Application of plasma circulating microRNA-448, 506, 4316, and 4478 analysis for non-invasive diagnosis of lung cancer
- PMID: 26341493
- DOI: 10.1007/s13277-015-3971-4
Application of plasma circulating microRNA-448, 506, 4316, and 4478 analysis for non-invasive diagnosis of lung cancer
Abstract
Aberrant expression of microRNAs (miRNAs) in cancer patients compared to healthy people as well as possibility of detection of these molecules in blood samples make them potential biomarkers of various cancers. In the present study, we investigated the potential role of four miRNAs as lung cancer (LC) biomarkers: miRNA-448, 506, 4316, and 4478. Using quantitative reverse transcription polymerase chain reaction (qRT-PCR) technique, we assessed expression of studied miRNAs in plasma samples of 90 lung cancer patients and 85 healthy individuals. Receiver operating curves (ROC) with area under the curve (AUC) were used to assess accuracy of studied miRNAs for distinguishing LC patients from healthy individuals. The miRNA-448 and 4478 were significantly overexpressed in lung cancer patients compared to healthy people and these two molecules were qualified for further analysis. Combination ROC analysis of both biomarkers reached 90 % of sensitivity and 76.3 % of specificity (AUC = 0.896) for distinguishing operable (stage IA-IIB) non-small cell lung cancer (NSCLC) patients from healthy subjects. Our results suggest that the examination of miRNAs could be considered as potential lung cancer, non-invasive biomarkers.
Keywords: Biomarkers; Early detection; Lung cancer; miRNA-4478; miRNA-448.
Similar articles
-
Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers.Transl Res. 2015 Oct;166(4):315-23. doi: 10.1016/j.trsl.2015.05.009. Epub 2015 May 29. Transl Res. 2015. PMID: 26079400
-
Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.Tumour Biol. 2016 Jun;37(6):7777-84. doi: 10.1007/s13277-015-4608-3. Epub 2015 Dec 22. Tumour Biol. 2016. PMID: 26695145
-
miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.J Thorac Oncol. 2011 Mar;6(3):482-8. doi: 10.1097/JTO.0b013e318208c785. J Thorac Oncol. 2011. PMID: 21258252
-
Clinical significance of circulating miRNA detection in lung cancer.Med Oncol. 2016 May;33(5):41. doi: 10.1007/s12032-016-0757-5. Epub 2016 Mar 31. Med Oncol. 2016. PMID: 27034265 Review.
-
Clinical use of microRNAs as potential non-invasive biomarkers for detecting non-small cell lung cancer: a meta-analysis.Respirology. 2015 Jan;20(1):56-65. doi: 10.1111/resp.12444. Epub 2014 Dec 1. Respirology. 2015. PMID: 25440223 Review.
Cited by
-
A 5-microRNA signature identified from serum microRNA profiling predicts survival in patients with advanced stage non-small cell lung cancer.Carcinogenesis. 2019 Jul 4;40(5):643-650. doi: 10.1093/carcin/bgy132. Carcinogenesis. 2019. PMID: 30428030 Free PMC article.
-
Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.J Clin Med. 2019 Oct 11;8(10):1661. doi: 10.3390/jcm8101661. J Clin Med. 2019. PMID: 31614612 Free PMC article. Review.
-
A microRNA profile of pediatric glioblastoma: The role of NUCKS1 upregulation.Mol Clin Oncol. 2019 Mar;10(3):331-338. doi: 10.3892/mco.2019.1795. Epub 2019 Jan 2. Mol Clin Oncol. 2019. PMID: 30847170 Free PMC article.
-
miR-448 promotes progression of non-small-cell lung cancer via targeting SIRT1.Exp Ther Med. 2019 Sep;18(3):1907-1913. doi: 10.3892/etm.2019.7738. Epub 2019 Jul 5. Exp Ther Med. 2019. PMID: 31410153 Free PMC article.
-
Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.Oncologist. 2016 Sep;21(9):1121-30. doi: 10.1634/theoncologist.2016-0082. Epub 2016 Jul 7. Oncologist. 2016. PMID: 27388233 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical